Company Quick10K Filing
Applied Dna Sciences
10-Q 2020-03-31 Filed 2020-05-14
10-Q 2019-12-31 Filed 2020-02-06
10-K 2019-09-30 Filed 2019-12-12
S-1 2019-09-18 Public Filing
10-Q 2019-06-30 Filed 2019-08-13
10-Q 2019-03-31 Filed 2019-05-09
10-Q 2018-12-31 Filed 2019-02-07
10-K 2018-09-30 Filed 2018-12-18
10-Q 2018-06-30 Filed 2018-08-13
10-Q 2018-03-31 Filed 2018-05-03
10-Q 2017-12-31 Filed 2018-02-08
10-K 2017-09-30 Filed 2017-12-28
10-Q 2017-06-30 Filed 2017-08-10
10-Q 2017-03-31 Filed 2017-05-11
10-Q 2016-12-31 Filed 2017-02-09
10-K 2016-09-30 Filed 2016-12-06
10-Q 2016-06-30 Filed 2016-08-11
10-Q 2016-03-31 Filed 2016-05-12
10-Q 2015-12-31 Filed 2016-02-10
10-K 2015-09-30 Filed 2015-12-14
10-Q 2015-06-30 Filed 2015-08-10
10-Q 2015-03-31 Filed 2015-05-11
10-Q 2014-12-31 Filed 2015-02-09
10-K 2014-09-30 Filed 2014-12-15
10-Q 2014-06-30 Filed 2014-08-11
10-Q 2014-03-31 Filed 2014-05-12
10-Q 2013-12-31 Filed 2014-02-10
10-K 2013-09-30 Filed 2013-12-20
10-Q 2013-06-30 Filed 2013-08-13
10-Q 2013-03-31 Filed 2013-05-15
10-Q 2012-12-31 Filed 2013-02-14
10-K 2012-09-30 Filed 2012-12-20
10-Q 2012-06-30 Filed 2012-08-14
10-Q 2012-03-31 Filed 2012-05-15
10-Q 2011-12-31 Filed 2012-02-14
10-K 2011-09-30 Filed 2011-12-09
10-Q 2011-06-30 Filed 2011-08-10
10-Q 2011-03-31 Filed 2011-05-16
10-Q 2010-12-31 Filed 2011-02-14
10-K 2010-09-30 Filed 2010-12-15
10-Q 2010-06-30 Filed 2010-08-13
10-Q 2010-03-31 Filed 2010-05-10
10-Q 2009-12-31 Filed 2010-02-11
8-K 2020-05-14 Earnings, Exhibits
8-K 2020-05-13 Other Events
8-K 2020-05-05 Regulation FD, Exhibits
8-K 2020-02-06 Earnings, Exhibits
8-K 2019-12-12 Earnings, Exhibits
8-K 2019-12-04 Leave Agreement
8-K 2019-11-21 Other Events, Exhibits
8-K 2019-11-15 Regulation FD, Other Events, Exhibits
8-K 2019-11-13 Enter Agreement, Other Events, Exhibits
8-K 2019-11-07 Officers, Regulation FD, Exhibits
8-K 2019-10-31 Amend Bylaw, Shareholder Vote, Regulation FD, Exhibits
8-K 2019-10-01 Regulation FD, Exhibits
8-K 2019-08-22 Enter Agreement, Sale of Shares, Exhibits
8-K 2019-08-13 Earnings, Exhibits
8-K 2019-08-06 Enter Agreement, M&A, Regulation FD, Exhibits
8-K 2019-07-30
8-K 2019-07-16 Enter Agreement, Off-BS Arrangement, Sale of Shares, Other Events, Exhibits
8-K 2019-05-16 Shareholder Vote
8-K 2019-05-09 Earnings, Exhibits
8-K 2019-03-28 Enter Agreement
8-K 2019-02-07 Earnings, Exhibits
8-K 2019-01-29
8-K 2019-01-25 Regulation FD
8-K 2018-12-26 Regulation FD, Exhibits
8-K 2018-12-21 Enter Agreement, Exhibits
8-K 2018-12-13 Earnings, Exhibits
8-K 2018-12-06 Regulation FD, Exhibits
8-K 2018-11-29 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-09-20
8-K 2018-08-31 Enter Agreement, Off-BS Arrangement, Sale of Shares, Other Events, Exhibits
8-K 2018-08-13 Earnings, Exhibits
8-K 2018-05-03 Earnings, Exhibits
8-K 2018-03-31 Regulation FD, Exhibits
8-K 2018-02-27 Shareholder Vote
8-K 2018-02-08 Earnings, Exhibits

Applied Dna Sciences Financials

APDN Metrics, Comps, Filings

Quarterly | Annual

Business

Using its proprietary large-scale PCR based manufacturing technology and systems, Applied DNA Sciences Inc. (“Applied DNA”, the “Company” or “we”) manufactures large quantities of linear DNA for use in its proprietary products as well as for sale to third parties. The Company manufactures non-biological DNA-based molecular taggants for use in its proprietary supply chain security, anticounterfeiting, brand protection and law enforcement products. With secure non-biological taggants, high-resolution DNA authentication, and comprehensive reporting, the Company's SigNature® molecular taggant technologies deliver what we believe to be the greatest levels of security, deterrence and legal recourse strength, making Applied DNA a leader in supply chain provenance technologies. The Company's 98% percent owned subsidiary LineaRx, Inc. (“LRx”) manufactures larger DNA constructs used in preclinical biotherapeutic applications, which are primarily sold to third parties. Through LRx, the Company supplies PCR produced linear DNA for use in preclinical biotherapeutic applications including CAR T/TCR, RNA manufacture, DNA-based vaccines and gene therapies, as well as in vitro diagnostics. LRx seeks to supplant the use of plasmid derived DNA with PCR-produced linear DNA in biotherapeutic and diagnostic applications, and to develop, acquire and commercialize, alone or with partners, a diverse portfolio of nucleic acid-based biotherapeutics and diagnostics that we believe will improve the efficacy, safety and cost of existing and newly developed biotherapeutics and diagnostics.

SigNature® molecular tags, the core of our supply chain security technology platform, are what we believe to be nature's ultimate means of authentication and supply chain security. We believe our precision-engineered molecular tags have not been broken. Additional layers of protection and complexity are added to the mark in a proprietary manner. SigNature® molecular tags in various carriers have proven highly resistant to UV radiation, heat, cold, vibration, abrasion and other extreme environments and conditions. We work closely with our customers to develop solutions that will be optimized to their specifications to deliver maximum impact. Our products and technology are protected by what we believe to be a robust portfolio of patents and trademarks.

Using our tagging products and technology, manufacturers, brands, and other stakeholders can ensure authenticity and protect against diversion throughout a product's journey from manufacturer to use.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Helios & Matheson Analytics (HMNY) 27,152 -109% -9.8 -210% 132,707 60,624 211,720 -230,220 -278,567 -2,874 28,224
Dolphin Entertainment (DLPN) 16,585 16% 12.4 -3% 37,608 29,890 18,539 3,000 -1,120 1,211 15,067
Yogaworks (YOGA) 11,783 63% -0.9 -45% 27,359 19,554 46,134 28,843 -12,329 -8,301 7,501
Spark Networks (LOV) 10,910 0% 62,862 43,453 0 0 0 0 10,910
Ascent Capital (ASCMA) 9,179 58% -0.0 590% 30,193 2,109 529,289 304,494 178,223 462,356 -20,583
XpresSpa Group (XSPA) 4,815 24% -1.0 -40% 33,718 29,181 37,669 9,029 -13,571 -6,928 7,131
Applied Dna Sciences (APDN) 288 84% 0.0 -242% 3,565 4,413 5,389 4,511 -8,623 -8,218 -271
Arco Platform (ARCE)
ATA Creativity Global (AACG)
Youdao (DAO)
Tarena (TEDU) 0% 2,282,645 628,460 0 0 0 0 -686,691
Crestwood Equity Partners (CEQP) 19% 6.4 5% 5,448,100 2,913,000 2,342,200 452,000 272,700 356,300 2,265,800
OneSmart International Education Group (ONE)
StoneMor Partners (STON) 8% -4.9 -7% 1,730,523 1,777,048 306,540 24,193 -120,118 -60,999 298,581
WW International (WW) 56% 7.1 9% 1,516,443 2,236,384 1,411,140 796,751 134,018 201,270 1,435,338
ManTech International (MANT) 11% -0.2 4% 2,077,839 622,883 2,115,218 239,883 93,461 162,287 -33,313
Verb Technology (VERB) 46% 0.4 -21% 29,015 11,416 6,615 3,052 -6,126 -4,886 -1,885
LAIX (LAIX) 0% 950,383 731,489 0 0 0 0 -344,722
Sunlands Technology Group (STG) 0% 3,739,138 4,078,121 0 0 0 0 -990,685
Four Seasons Education (FEDU) 0% 932,054 175,123 0 0 0 0 -471,235

Balance Sheet ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash122,7471,9368571,2567259844,4061,8326,3604,1991,9882,0261,3932,87298410,7307,31212,3839,7867,0874,4796,7024,0202,4032,9604,7653,7092,5151,6603,1381,541507559
Accounts Receivable1782092333244432973624085886737496065188351,1151,1602,0783,9303,9245,0274,7926,3756,1565,1924,7462,5882,1561,5261,4151,486615316244840
Inventory127298323354377326314294295221225315310143
PP&E089821213664634634931,0021,1061,2081,2231,3151,3355215885271,4255628798062,0567246725902,1905005515362,4563693162652,519
Assets8943,5042,5221,4521,9701,3491,6255,0733,8418,3756,2413,7823,7713,5065,0223,62714,12315,55420,48517,71215,21915,56616,77013,21710,4238,1549,6097,9346,6085,6346,1494,2262,9853,565
Accounts Payable2144736036851,2496417709869051,0608869987701,2381,5991,9091,4791,5301,6581,1581,0163836024393875019446428391,152
Long-Term Debt2500320
Liabilities4,4993,8766386545928,3238,8441,5333,7594,3584,1033,4604,9751,7211,6711,6232,9872,4892,6843,0335,2004,5883,9262,4051,2961,4702,2263,5504,8795,3834,9604,7744,413
Stockholders' Equity-995-1,3548141,316757-6,698-3,7712,3084,6161,882-320311-1,4683,3011,95512,50012,56717,99615,02812,18610,36512,1829,2918,0186,8588,1385,7073,058755766-734-1,789-841
Income Statement ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue2302815175185292913183456457295976378416461,2421,5192,2683,9801,3245736531,6369039051,7978476481,0441,0161,1958847782,0531,673
Cost of Revenue121442275297232273331372253251153133271320
Gross Profit5321,1946286081,5655743166727649457316451,7831,353
R&D4810778961001581481761851834593602662152783733106744727291,078832519636603525740670625717710651720887
SG&A1,5813,8602,1521,8251,7531,8862,5212,7543,2412,6823,8463,2982,9483,1564,6712,9013,5083,6583,5543,1202,7072,6233,9013,2303,4032,7902,5931,9972,8823,5723,0822,5292,4072,260
Tax00000000000000000000000000000000015
Net Income-2,155-2,410-1,544-1,430-1,767-8,705-3,128-2,136-3,718-6,292-2,750-1,919-2,106-7,829-1,886-1,671-496-2,926-3,468-3,367-2,415-3,961-3,429-2,611-2,855-3,184-2,146-2,888-3,475-3,234-2,687-1,478-1,224
Cash Flow ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-812-1,032-1,124-993-1,740-2,149-1,808-2,173-2,066-2,196-2,008-2,242-2,356-1,616-1,255-1,739-2,721-2,503-2,227-2,446-2,069-2,630-1,866-914-2,573-707-2,509-1,514-2,288-1,283-1,777
Cash Investing0-47-19-970-30-768-423-95-15-100-20-31-202-227-1,679-66-94-472-147-43-51-18-34-48-1554-52-12-41
Cash Financing5582,0005,60027,12501,6293,865-7011,22807,85800-144,33402661,5054,426-1931,6503,0447042541,827